polaris tirzepatide cuts risk of diabetes by 94% in adults with prediabetes and obesity or overweight, drugmaker says Tirzepatide 5mg - polaris peptides
Description
If the SOUL study corroborates the findings of this model, it may not only form the basis for the calculation of power but also define the duration of such studies, reducing costs and easing the process of designing cardiovascular outcome trials (CVOTs)
Available for pre-order
Notably, glucagon-like peptide-1 (GLP-1)-based drugs are being successfully used to control glucose levels in patients with diabetes mellitus
Improvement in lipid profile (reduction in triglycerides and LDL cholesterol)
